CN104926926B - A kind of refining methd of enramycin - Google Patents
A kind of refining methd of enramycin Download PDFInfo
- Publication number
- CN104926926B CN104926926B CN201510078756.2A CN201510078756A CN104926926B CN 104926926 B CN104926926 B CN 104926926B CN 201510078756 A CN201510078756 A CN 201510078756A CN 104926926 B CN104926926 B CN 104926926B
- Authority
- CN
- China
- Prior art keywords
- enramycin
- solvent
- solution obtained
- acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NJCUSQKMYNTYOW-MWUYRYRWSA-N enramicina Chemical compound O.N1C(=O)NC(=O)C(C=2C=C(Cl)C(O)=C(Cl)C=2)NC(=O)C(CO)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(CC2N=C(N)NC2)NC(=O)C(CCCNC(N)=O)NC(=O)C(C(C)O)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C(C)O)NC(=O)N(CCCCN)C(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)/C=C/C=C/CCCCC(C)CC)C(C)OC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C)NC(=O)C1CC1CNC(N)=N1 NJCUSQKMYNTYOW-MWUYRYRWSA-N 0.000 title claims abstract description 64
- 108700041171 enramycin Proteins 0.000 title claims abstract description 64
- 229950003984 enramycin Drugs 0.000 title claims abstract description 64
- 238000007670 refining Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 238000009776 industrial production Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 239000012043 crude product Substances 0.000 abstract description 2
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- JPYWPHBUMZRLPO-DLYWSANHSA-N 5tq7z201b8 Chemical compound C([C@H]1C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@H](C[C@H]2NC(N)=NC2)C(=O)N[C@H](C(=O)N[C@H](CO)C(=O)N[C@H](C(=O)NCC(=O)N1)C=1C=C(Cl)C(O)=C(Cl)C=1)C=1C=CC(O)=CC=1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(O)=O)NC(=O)\C=C/C=C/CCCCC(C)CC)C=1C=CC(O)=CC=1)[C@@H]1CN=C(N)N1 JPYWPHBUMZRLPO-DLYWSANHSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004896 polypeptide structure Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000006030 antibiotic growth promoter Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to the refining methds of enramycin (Enramycin) a kind of, the method includes enramycin crude product is configured to certain density solution, then adjusts its pH value and finally realize precipitating, to obtain the enramycin of high-purity.This method simple process, strong operability, obtained product purity and high income are extremely suitable for industrial production.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a refining method of Enramycin (Enramycin).
Background
Enramycin (Enramycin) is a polypeptide antibiotic produced by fermentation of the actinomycete streptomyces fungicidious No. b5477 isolated from soil, which is a combination of unsaturated fatty acids and over ten amino acids. Wherein the amino acid molecule forms a cyclic polypeptide structure, the fatty acid is located at the tail end of the polypeptide structure, and the polypeptide is divided into enramycin A (C) according to different types of the terminal fatty acid107H138Cl2N26O31) And enramycin B (C)108H140Cl2N26O31). The commonly mentioned enramycin is a mixture mainly composed of the two components (see the structure formula 1). The drug was developed by wutian drug industry co, japan in 1966, officially registered in japan in 1974, and thereafter registered and widely used in many countries. In 1993, the medicine is successfully registered in China and is used as a medicine feed additive. The enramycin has strong inhibition effect on gram-positive bacteria, is not easy to generate drug resistance after long-term use and has high resistanceThe enramycin is not easy to be absorbed by the human body internally, the medicine is mainly discharged out of the human body through excrement, and the residual in the livestock and poultry body is less. In addition, it can change the distribution of bacterial communities in intestinal tracts, is beneficial to the digestion and absorption of nutrient components of the feed, promotes the weight increment of animals and improves the utilization rate of the feed, so that the feed additive is recommended by many countries in the world as an antibiotic growth promoter and is an excellent feed additive.
At present, enramycin used in the market is an enramycin premix, wherein enramycin is not purified. For example, the methods disclosed in patent ZL201010198230.5 and CN201210120843.6, which are both prepared by directly preparing a premix from fermentation liquor containing enramycin. With the continuous development of production technology, researchers are continuously improving the quality of enramycin products. For example, patent CN201210433028.5 discloses a method for preparing crude enramycin, the purity of which can reach about 70%; CN201210153458.1 discloses a method for obtaining enramycin with purity of more than 90 percent by macroporous adsorption resin purification; the patent ZL201010213986.2 relates to a method for separating and extracting enramycin by utilizing macroporous weak-acid cation exchange resin, and the purity of the enramycin can reach more than 95% by the method; the patent ZL201110344875.X relates to a method for extracting, separating and purifying enramycin from enramycin fermentation liquor, and the method comprises the following steps of carrying out thermal treatment on the enramycin fermentation liquor, filtering, centrifuging and collecting thalli; adding methanol solution into the thallus, performing ultrasonic treatment, and filtering; acidifying and alkalizing the filtrate, then decoloring, adsorbing the decolored solution by macroporous adsorption resin, eluting by methanol, collecting eluent, concentrating and crystallizing, and freeze-drying to obtain enramycin, wherein the purity of the enramycin obtained by the method reaches about 95%; CN201310730536.4 discloses a method for purifying and obtaining more than 99% of enramycin by a method of combining weak acid and weak base macroporous adsorption resin. In addition, ZL201210433029.X relates to a method for preparing high-purity enramycin A and enramycin B by reverse phase chromatography, and ZL201210159394.6 relates to a method for preparing enramycin standard by high pressure liquid phase.
In the prior art, the yield of enramycin is too low by adopting a method of adjusting the pH value to be below 2.0, precipitating, heating and drying; some methods adopt freeze drying, so that the production cost is too high; some column chromatography methods increase the operation steps, and the methods are not suitable for industrial production. Therefore, the method provided by the invention has the characteristics of simple process, strong operability, low cost and the like, and the obtained product has high purity and high yield, and is more suitable for industrial production.
Disclosure of Invention
Aiming at the technical defects in the existing enramycin refining process, the invention aims to provide a method for refining enramycin, which is suitable for industrial production.
The invention relates to a refining method of enramycin, which makes enramycin precipitate by adjusting the concentration of enramycin in an enramycin solution, the volume percentage of an organic solvent and the pH value of the solution, thereby obtaining a high-purity enramycin product.
The method is realized by the following technical scheme:
a refining method of enramycin, which comprises the following steps:
(a) dissolving enramycin in an acidic aqueous solution containing an organic solvent; or
(a') dissolving enramycin in a mixed solvent containing an organic solvent and water, followed by adjusting the pH of the resulting solution to acidity with an acid; and
(b) adjusting the pH value of the solution obtained in the step (a) or (a') by using alkali, thereby obtaining a precipitate of enramycin.
Wherein the pH value of the acidic aqueous solution in the step (a) is 2.0-5.0, preferably 2.0-4.0, and more preferably 2.5-3.5.
Wherein the pH of the solution obtained in step (a') is adjusted to a value of 2.0 to 5.0, preferably 2.0 to 4.0, more preferably 2.5 to 3.5.
Wherein in step (b), the pH of the solution obtained in step (a) or (a') is adjusted to 6.5-9.0, preferably 7.0-8.5, with a base.
Wherein, the concentration of the enramycin in the solution obtained in the step (a) or (a') is 100-150g/L, preferably 110-140 g/L.
Wherein, the organic solvent in step (a) or (a') is an alcohol solvent, including but not limited to methanol, ethanol or isopropanol, preferably methanol or ethanol, more preferably methanol, and the volume percentage of the alcohol solvent in the mixed solvent is 60% -90%, preferably 65% -88%, more preferably 70-85%.
Wherein the acid of step (a') is selected from hydrochloric acid, nitric acid or sulfuric acid, preferably hydrochloric acid.
Wherein the alkali used in step (b) is selected from sodium hydroxide or potassium hydroxide, preferably sodium hydroxide.
In a preferred embodiment of the invention, step (a) or (a') controls the pH of the solution in the range of 2.0 to 5.0, preferably 2.0 to 4.0, more preferably 2.5 to 3.5, on the one hand to increase the solubility of enramycin and, on the other hand, to improve the stability of enramycin.
In the invention, the experiment on the influence of the content of the alcohol solvent on the precipitation proves that when the volume percentage content of the alcohol solvent is 50-90%, preferably 65-88%, and more preferably 70-85%, the process operation and the product purity are favorably improved.
The method has the advantages of high purity and yield of the final product, simple operation, good repeatability and low cost, and is very suitable for industrial production.
Drawings
FIG. 1 XRPD pattern of enramycin prepared from 80% aqueous methanol as in example 1
Detailed Description
The present invention will be further explained with reference to examples, but the present invention is not limited thereto.
The X-ray powder diffraction instrument and the test conditions related by the invention are as follows: x-ray diffraction apparatus model Rigaku D/max-2200Cu target; the operation method comprises the following steps: the scanning speed is 4 degrees/min, and the scanning step width is 0.01 degrees.
The liquid phase test conditions involved in the invention are as follows: the chromatographic column is as follows: agilet HC-C184.6X 250mm 5 μm; the mobile phase is as follows: buffer (3.0ml phosphoric acid +500ml water, pH 3.8 adjusted with NaOH)/methanol/acetonitrile 500/300/200; detection wavelength: 232 nm; flow rate: 1.0 ml/min; column temperature: 35 ℃ is carried out.
Example 1
450g of each of 3 parts of crude enramycin (HPLC purity 88.6%) was dissolved in 500mL of each of 80% methanol aqueous solution, 80% ethanol aqueous solution and 80% isopropanol aqueous solution (pH 3), and then the pH of each solution was adjusted to 7.5 with sodium hydroxide to precipitate enramycin solid, which was filtered, collected and dried to obtain enramycin having the purity and yield shown in Table 1. The XRPD pattern of enramycin prepared from 80% methanol in water is shown in figure 1.
TABLE 1
Example 2
450g of each 8 parts of crude enramycin (HPLC purity 88.6%) are dissolved in 500mL of 50%, 60%, 65%, 70%, 80%, 85%, 88% and 90% aqueous methanol solutions, the pH of each solution is adjusted to 3.0 with hydrochloric acid, the pH of each solution is adjusted to 7.5 with sodium hydroxide, enramycin solids are precipitated, filtered, collected and dried, and the enramycin purity and yield are shown in Table 2.
TABLE 2
Example 3
The enramycin crude products (HPLC purity 88.6%) are prepared into 500mL solutions with the concentrations shown in Table 3 by using 80% methanol aqueous solution (pH value is 3), then the pH value of each solution is adjusted to 7.5 by using sodium hydroxide, enramycin solid is separated out, the solid is filtered, collected and dried, and the purity and the yield of the enramycin are shown in Table 3.
TABLE 3
Example 4
450g of each of 12 parts of crude enramycin (88.6% purity by HPLC) was dissolved in 80% aqueous methanol (pH 3) to prepare 500mL of a solution, and the pH of each solution was adjusted according to the following Table 4, and the results are shown in Table 4 below.
TABLE 4
Claims (19)
1. A refining method of enramycin, which is characterized by comprising the following steps:
(a) dissolving enramycin in an acidic aqueous solution containing an organic solvent; or
(a') dissolving enramycin in a mixed solvent containing an organic solvent and water, followed by adjusting the pH of the resulting solution to acidity with an acid; and
(b) adjusting the pH value of the solution obtained in the step (a) or (a') by using alkali, thereby obtaining a precipitate of enramycin;
wherein,
the concentration of the enramycin in the solution obtained in the step (a) or (a') is 100-150g/L,
the organic solvent in the step (a) or (a') is an alcohol solvent, and the volume percentage of the alcohol solvent in the mixed solvent is 60-90%.
2. The method of claim 1, wherein the pH of the acidic aqueous solution of step (a) is from 2.0 to 5.0.
3. The method according to claim 1 or 2, wherein the pH of the acidic aqueous solution of step (a) is 2.0-4.0.
4. The method according to claim 1 or 2, wherein the pH of the acidic aqueous solution of step (a) is 2.5-3.5.
5. The process according to claim 1, wherein the pH of the solution obtained in step (a') is adjusted to a value of 2.0 to 5.0.
6. The process according to claim 5, wherein the pH of the solution obtained in step (a') is adjusted to a value of 2.0 to 4.0.
7. The process according to claim 5 or 6, wherein the pH of the solution obtained in step (a') is adjusted to a value of 2.5 to 3.5.
8. The method of claim 1, wherein in step (b), the pH of the solution obtained in step (a) or (a') is adjusted to 6.5-9.0 with a base.
9. The method according to claim 8, wherein in step (b), the pH of the solution obtained in step (a) or (a') is adjusted to 7.0 to 8.5 with a base.
10. The method as claimed in any one of claims 1 to 9, wherein the concentration of enramycin in the solution obtained in step (a) or (a') is 110-140 g/L.
11. The method according to any one of claims 1 to 9, wherein the alcohol solvent is contained in the mixed solvent in an amount of 65 to 88% by volume.
12. The method according to any one of claims 1 to 9, wherein the alcohol solvent is contained in the mixed solvent in an amount of 70 to 85% by volume.
13. The method according to claim 11 or 12, wherein the alcoholic solvent is methanol, ethanol or isopropanol.
14. The method of claim 13, wherein the alcoholic solvent is methanol or ethanol.
15. The method of claim 14, wherein the alcoholic solvent is methanol.
16. The method according to any one of claims 1 to 9, wherein the acid of step (a') is selected from hydrochloric acid, nitric acid or sulfuric acid.
17. The method of claim 16, wherein the acid of step (a') is selected from hydrochloric acid.
18. The process of any one of claims 1 to 9, wherein the base of step (b) is selected from sodium hydroxide or potassium hydroxide.
19. The method of claim 18, wherein the base of step (b) is selected from sodium hydroxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510078756.2A CN104926926B (en) | 2015-02-13 | 2015-02-13 | A kind of refining methd of enramycin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510078756.2A CN104926926B (en) | 2015-02-13 | 2015-02-13 | A kind of refining methd of enramycin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104926926A CN104926926A (en) | 2015-09-23 |
| CN104926926B true CN104926926B (en) | 2019-09-27 |
Family
ID=54114369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510078756.2A Active CN104926926B (en) | 2015-02-13 | 2015-02-13 | A kind of refining methd of enramycin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104926926B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105131090A (en) * | 2015-10-15 | 2015-12-09 | 山西新源华康化工股份有限公司 | Dissolving solution for purifying enramycin and method for purifying enramycin |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
| CN102382177A (en) * | 2011-11-03 | 2012-03-21 | 安徽丰原发酵技术工程研究有限公司 | Method for extracting, separating and purifying enramycin |
| CN102898509A (en) * | 2012-11-04 | 2013-01-30 | 乐占线 | Method for preparing enramycin crude product |
| CN103709235A (en) * | 2013-12-26 | 2014-04-09 | 福建省福抗药业股份有限公司 | Method for reducing solvent use amount and extracting high-purity enramycin |
| CN103740612A (en) * | 2013-12-19 | 2014-04-23 | 河北圣雪大成制药有限责任公司 | High-yield enramycin strain and screening method thereof |
-
2015
- 2015-02-13 CN CN201510078756.2A patent/CN104926926B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
| CN102382177A (en) * | 2011-11-03 | 2012-03-21 | 安徽丰原发酵技术工程研究有限公司 | Method for extracting, separating and purifying enramycin |
| CN102898509A (en) * | 2012-11-04 | 2013-01-30 | 乐占线 | Method for preparing enramycin crude product |
| CN103740612A (en) * | 2013-12-19 | 2014-04-23 | 河北圣雪大成制药有限责任公司 | High-yield enramycin strain and screening method thereof |
| CN103709235A (en) * | 2013-12-26 | 2014-04-09 | 福建省福抗药业股份有限公司 | Method for reducing solvent use amount and extracting high-purity enramycin |
Non-Patent Citations (3)
| Title |
|---|
| 大孔树脂吸附与反相色谱纯化恩拉霉素;吴家鑫等;《生物工程学报》;20141125;第30卷(第11期);1701-1708 * |
| 恩拉霉素的最新研究进展;张子臣等;《中国抗生素杂志》;20130331;第38卷(第3期);185-190 * |
| 饲料中恩拉霉素的微生物学含量测定方法研究;顾欣等;《中国兽药杂志》;20081231;第42卷(第9期);17-21 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104926926A (en) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10131689B2 (en) | Separation and purification method for vancomycin hydrochloride of high purity | |
| CN110590867B (en) | Synthesis method of D-glucosamine hydrochloride | |
| CN103555807A (en) | Method for preparing 7-ACA (aminocephalosporanic acid) and obtaining alpha-aminoadipic acid by one-step enzymatic reaction | |
| CN108250270A (en) | A kind of method of the enrichment extraction Daptomycin from zymotic fluid | |
| CN104926926B (en) | A kind of refining methd of enramycin | |
| CN109666051B (en) | Purification method of kasugamycin | |
| CN105524129A (en) | Etimicin sulfate preparation method | |
| CN116425810B (en) | Purification method of 3-fucosyllactose in mixed solution | |
| CN107033114B (en) | Method for separating and purifying dihydromyricetin | |
| CN109293722B (en) | Azithromycin related substance and preparation method thereof | |
| CN109096347B (en) | Method for purifying high-purity 3,2 ', 6' -tri-N-acetyl gentamicin C1a alkali (P1) | |
| CN116332822A (en) | Method for preparing low-chroma 5-hydroxytryptophan from garna seeds | |
| CN107129456B (en) | Production process for extracting L-tryptophan from fermentation liquor | |
| CN112194693B (en) | Separation and purification method of doramectin | |
| CN102617327B (en) | Dexibuprofen compound and preparation method thereof | |
| CN107739307B (en) | Method for purifying protocatechuic acid by using dilute alkali solution extraction-solid phase extraction column | |
| CN103570573B (en) | Method for extracting alpha-aminoadipic acid from enzymatic waste liquor | |
| CN110563782B (en) | Gentamicin C 1a Purification method of (2) | |
| CN106928290A (en) | A kind of preparation method of high content rutin | |
| CN109796333B (en) | Method for extracting and purifying pravastatin sodium from fermentation liquor | |
| CN112390806A (en) | Method for improving extraction yield of spectinomycin | |
| CN113045610A (en) | Method for extracting glucosamine from N-acetylglucosamine fermentation liquor | |
| CN105713004A (en) | Preparation method for high-quality irinotecan hydrochloride trihydrate crystal forms | |
| CN113045611A (en) | Preparation method of high-purity lincomycin hydrochloride | |
| CN113698289B (en) | Method for preparing shikimic acid from ginkgo leaf extraction waste liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |